Brought to you by 
Basilea gets CHF324.3mm via private financing
30 Mar 2007
Executive Summary
In an oversubscribed PIPE financing to institutional investors, Basilea Pharmaceutica (dermatology and infectious disease therapeutics) sold 1.38mm common shares (including the overallotment) at CHF235 each, a 4% discount to market, for gross proceeds of CHF324.3mm ($267.3mm). The company will use some of the funds to commercialize three Phase III candidates.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Basilea gets CHF324.3mm via private financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice